Nemes Rush Group’s Biogen BIIB Stock Holding History

Nemes Rush Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$183	Hold	1	–	–	﹤0.01%	923
2025 Q4	$176	Buy	+1	New	+$163	﹤0.01%	936

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nemes Rush Group's BIIB Position: Q1 2026 in Review

Nemes Rush Group held its Biogen (BIIB) position steady in Q1 2026 at 1 share worth $183. The position accounts for ﹤0.01% of the portfolio, ranked #923.

Nemes Rush Group first reported a position in BIIB in Q4 2025 and has held it in 2 quarters since. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Nemes Rush Group held 1 share of Biogen worth $183 as of Q1 2026.
Nemes Rush Group left its Biogen share count unchanged in Q1 2026.
Biogen made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #923 holding.
Nemes Rush Group first reported a position in Biogen in Q4 2025 and has held it in 2 quarters since.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.